Last reviewed · How we verify
TT infant whole Pertussis
This is a whole-cell pertussis vaccine that stimulates the immune system to produce antibodies and cellular immunity against Bordetella pertussis bacteria.
This is a whole-cell pertussis vaccine that stimulates the immune system to produce antibodies and cellular immunity against Bordetella pertussis bacteria. Used for Pertussis (whooping cough) prevention in infants.
At a glance
| Generic name | TT infant whole Pertussis |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The TT infant whole pertussis vaccine contains inactivated whole Bordetella pertussis cells that trigger both humoral (antibody) and cell-mediated immune responses in infants. This vaccine formulation was historically used as part of combination vaccines (such as DPT) to provide protection against pertussis infection. The whole-cell approach differs from acellular pertussis vaccines, which contain only specific bacterial antigens.
Approved indications
- Pertussis (whooping cough) prevention in infants
Common side effects
- Local injection site reactions (pain, swelling, redness)
- Fever
- Irritability
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT infant whole Pertussis CI brief — competitive landscape report
- TT infant whole Pertussis updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI